Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

•Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models.•Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells. [Display omitted]

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2019-08, Vol.3 (16), p.2448-2452
Hauptverfasser:	Yun, Hyun Don, Schirm, Dawn K., Felices, Martin, Miller, Jeffrey S., Eckfeldt, Craig E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biomarkers Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cell Line, Tumor Cytotoxicity, Immunologic - drug effects Disease Models, Animal Humans Immunomodulation - drug effects Immunophenotyping Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - metabolism Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Mice Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyridinium Compounds - pharmacology Pyridinium Compounds - therapeutic use Stimulus Report Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models.•Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells. [Display omitted]
ISSN:	2473-9529 2473-9537
DOI:	10.1182/bloodadvances.2019000064